newsfilter
← Latest News
GlobeNewswire·

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.

  • Editas Medicine, Inc. appointed Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors effective August 6, 2026.
  • Elliott Levy, M.D., stepped down from the Board of Directors as an independent director following three years of service.
  • Dr. Ellinor currently serves as Executive Director of the Mass General Brigham Heart and Vascular Institute.
  • Dr. Ellinor directs the Cardiovascular Disease Initiative at the Broad Institute of MIT and Harvard, overseeing research in human genetics, genomics, artificial intelligence, and therapeutic discovery.
  • The appointment aims to leverage Dr. Ellinor's expertise as the company advances EDIT-401 for the potential treatment of hyperlipidemia.
  • Editas Medicine is a gene editing company focused on developing in vivo medicines using CRISPR systems, holding exclusive licenses for Broad Institute's Cas12a and Cas9 patent estates.